Toralf Reimer
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 92
- Obstetrics and Gynecology top 1%
- Endometrial and Cervical Cancer Treatments 15
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 13
- Oncology top 2%
- Cancer Treatment and Pharmacology 23
- HER2/EGFR in Cancer Research 21
-
- Breast Lesions and Carcinomas 37
-
- Breast Implant and Reconstruction 32
-
- Advanced Breast Cancer Therapies 28
Toralf Reimer
188 papers receiving 4.2k citations
Peers
Comparison fields: 5 of 147
- Cancer Research 1.8k
- Obstetrics and Gynecology 583
- Reproductive Medicine 465
- Oncology 1.4k
- Pathology and Forensic Medicine 831
Countries citing papers authored by Toralf Reimer
This map shows the geographic impact of Toralf Reimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toralf Reimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toralf Reimer more than expected).
Fields of papers citing papers by Toralf Reimer
This network shows the impact of papers produced by Toralf Reimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toralf Reimer. The network helps show where Toralf Reimer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Toralf Reimer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 18 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 4 | |
| 8 | 2022 | 9 | |
| 9 | 2022 | 2 | |
| 10 | 2022 | 23 | |
| 11 | 2021 | 5 | |
| 12 | 2020 | 1 | |
| 13 | 2017 | 98 | |
| 14 | 2017 | 14 | |
| 15 | Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer | 2016 | 5 |
| 16 | 2015 | 21 | |
| 17 | 2012 | 43 | |
| 18 | 2009 | 2 | |
| 19 | 2002 | 83 | |
| 20 | 1999 | 10 |
About Toralf Reimer
Toralf Reimer is a scholar working on Cancer Research, Obstetrics and Gynecology, Oncology, Pathology and Forensic Medicine and Reproductive Medicine, having authored 202 papers that have together received 4.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (92 papers), Breast Lesions and Carcinomas (37 papers), Breast Implant and Reconstruction (32 papers), Advanced Breast Cancer Therapies (28 papers), Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (21 papers), Endometrial and Cervical Cancer Treatments (15 papers) and Ovarian cancer diagnosis and treatment (13 papers). The work is most often cited by research in Cancer Research (1.8k citations), Obstetrics and Gynecology (583 citations), Reproductive Medicine (465 citations), Oncology (1.4k citations) and Pathology and Forensic Medicine (831 citations). Toralf Reimer has collaborated with scholars based in Germany, United States and Austria. Frequent co-authors include Bernd Gerber, Annette Krause, Max Dieterich, Günther Kundt, Angrit Stachs, Klaus Friese, Johannes Stubert, Steffi Hartmann, B. Gerber and Heiner Müller. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and Breast Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.